Immune response evaluation through determination of type 1, type 2, and type 17 patterns in patients with epithelial ovarian cancer

Reproductive Sciences

Volumn 20, Issue 7, 2013, Pages 828-837

  Cândido, Eduardo Batista ^a   Silva, Luciana Maria ^b   Carvalho, Andréa Teixeira ^c   Lamaita, Rívia Mara ^d   Filho, Roberto Mundim Porto ^a   Cota, Bianca Della Croce Vieira ^b   Da Silva Filho, Agnaldo Lopes ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b FUNDAÇÃO EZEQUIEL DIAS   (Brazil)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

^d Hospital Mater Dei   (Brazil)

Author keywords

adaptive immune response; cytokines; epithelial ovarian cancer; flow cytometry; type 1; type 17.; type 2

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; PACLITAXEL; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CONTROLLED STUDY; CYTOMETRY; CYTOREDUCTIVE SURGERY; FEMALE; GYNECOLOGIC DISEASE; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; OVARY CARCINOMA; OVERALL SURVIVAL; PERITONEAL FLUID; PRIORITY JOURNAL; TH1 CELL; TH17 CELL; TH2 CELL; TUMOR DIFFERENTIATION;

ADAPTIVE IMMUNE RESPONSE; CYTOKINES; EPITHELIAL OVARIAN CANCER; FLOW CYTOMETRY; TYPE 1; TYPE 17.; TYPE 2;

ADULT; AGED; FEMALE; HUMANS; IMMUNITY, CELLULAR; INTERLEUKIN-1; INTERLEUKIN-17; INTERLEUKIN-2; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROSPECTIVE STUDIES; SURVIVAL RATE; TH1 CELLS; TH17 CELLS; TH2 CELLS;

EID: 84878841858     PISSN: 19337191     EISSN: 19337205     Source Type: Journal    
DOI: 10.1177/1933719112466299     Document Type: Article

References (39)

1. Hennessy BT, Coleman RL, Markman M. Ovarian cancer. Lancet. 2009 ; 374 (9698). 1371-1382
2. Polverino G, Parazzini F, Stellato G, Scarfone G, Cipriani S, Bolis G. Survival and prognostic factors of women with advanced ovarian cancer and complete response after a carboplatin-paclitaxel chemotherapy. Gynecol Oncol. 2005 ; 99 (2). 343-347
3. Yigit R, Figdor CG, Zusterzeel PL, Pots JM, Torensma R, Massuger LF. Cytokine analysis as a tool to understand tumour-host interaction in ovarian cancer. Eur J Cancer. 2011 ; 47 (12). 1883-1889
4. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol. 1986 ; 136 (7). 2348-2357
5. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol. 2006 ; 6 (10). 715-727
6. Kulbe H, Thompson R, Wilson JL, et al. The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer Res. 2007 ; 67 (2). 585-592
7. Egberts JH, Cloosters V, Noack A, et al. Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis. Cancer Res. 2008 ; 68 (5). 1443-1450
8. Yue FY, Dummer R, Geertsen R, et al. Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules. Int J Cancer. 1997 ; 71 (4). 630-637
9. Torres MP, Ponnusamy MP, Lakshmanan I, Batra SK. Immunopathogenesis of ovarian cancer. Minerva Med. 2009 ; 100 (5). 385-400
10. Nilsson MB, Langley RR, Fidler IJ. Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. Cancer Res. 2005 ; 65 (23). 10794-10800
11. Nelms K, Keegan AD, Zamorano J, Ryan JJ, Paul WE. The IL-4 receptor: signaling mechanisms and biologic functions. Annu Rev Immunol. 1999 ; 17: 701-738
12. Kawakami K, Kawakami M, Puri RK. Overexpressed cell surface interleukin-4 receptor molecules can be successfully targeted for antitumor cytotoxin therapy. Crit Rev Immunol. 2001 ; 21 (1-3). 299-310
13. Kioi M, Takahashi S, Kawakami M, Kawakami K, Kreitman RJ, Puri RK. Expression and targeting of interleukin-4 receptor for primary and advanced ovarian cancer therapy. Cancer Res. 2005 ; 65 (18). 8388-8396
14. Giuntoli RL, Webb TJ, Zoso A, et al. Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity. Anticancer Res. 2009 ; 29 (8). 2875-2884
15. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003 ; 348 (3). 203-213
16. Raspollini MR, Castiglione F, Rossi Degl'innocenti D, et al. Tumour-infiltrating gamma/delta T-lymphocytes are correlated with a brief disease-free interval in advanced ovarian serous carcinoma. Ann Oncol. 2005 ; 16 (4). 590-596
17. Ouyang W, Kolls JK, Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity. 2008 ; 28 (4). 454-467
18. Kryczek I, Banerjee M, Cheng P, et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood. 2009 ; 114 (6). 1141-1149
19. van Nagell JR, Pavlik EJ. Ovarian cancer screening. Clin Obstet Gynecol. 2012 ; 55 (1). 43-51
20. Benedet JL, Bender H, Jones H, Ngan HY, Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet. 2000 ; 70 (2). 209-262
21. Rustin GJ, Timmers P, Nelstrop A, et al. Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide. J Clin Oncol. 2006 ; 24 (1). 45-51
22. Nowak M, Glowacka E, Szpakowski M, et al. Proinflammatory and immunosuppressive serum, ascites and cyst fluid cytokines in patients with early and advanced ovarian cancer and benign ovarian tumors. Neuro Endocrinol Lett. 2010 ; 31 (3). 375-383
23. Kavsak PA, Lee A, Hirte H, Young E, Gauldie J. Cytokine elevations in acute coronary syndrome and ovarian cancer: a mechanism for the up-regulation of the acute phase proteins in these different disease etiologies. Clin Biochem. 2008 ; 41 (7-8). 607-610
24. Darai E, Detchev R, Hugol D, Quang NT. Serum and cyst fluid levels of interleukin (IL) -6, IL-8 and tumour necrosis factor-alpha in women with endometriomas and benign and malignant cystic ovarian tumours. Hum Reprod. 2003 ; 18 (8). 1681-1685
25. Hagemann T, Wilson J, Burke F, et al. Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. J Immunol. 2006 ; 176 (8). 5023-5032
26. Wang T, Niu G, Kortylewski M, et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med. 2004 ; 10 (1). 48-54
27. Carr TM, Adair SJ, Fink MJ, Hogan KT. Immunological profiling of a panel of human ovarian cancer cell lines. Cancer Immunol Immunother. 2008 ; 57 (1). 31-42
28. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell. 2005 ; 7 (3). 211-217
29. Schuurhuis DH, van Montfoort N, Ioan-Facsinay A, et al. Immune complex-loaded dendritic cells are superior to soluble immune complexes as antitumor vaccine. J Immunol. 2006 ; 176 (8). 4573-4580
30. Gavalas NG, Karadimou A, Dimopoulos MA, Bamias A.. Immune response in ovarian cancer: how is the immune system involved in prognosis and therapy: potential for treatment utilization. Clin Dev Immunol. 2010 ; 2010: 791603
31. Schmeler KM, Vadhan-Raj S, Ramirez PT, et al. A phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer. Gynecol Oncol. 2009 ; 113 (2). 210-215
32. Scambia G, Testa U, Benedetti Panici P, et al. Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. Br J Cancer. 1995 ; 71 (2). 354-356
33. Tempfer C, Zeisler H, Sliutz G, Haeusler G, Hanzal E, Kainz C. Serum evaluation of interleukin 6 in ovarian cancer patients. Gynecol Oncol. 1997 ; 66 (1). 27-30
34. Offner FA, Obrist P, Stadlmann S, et al. IL-6 secretion by human peritoneal mesothelial and ovarian cancer cells. Cytokine. 1995 ; 7 (6). 542-547
35. Duan Z, Foster R, Bell DA, et al. Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. Clin Cancer Res. 2006 ; 12 (17). 5055-5063
36. Obata NH, Tamakoshi K, Shibata K, Kikkawa F, Tomoda Y. Effects of interleukin-6 on in vitro cell attachment, migration and invasion of human ovarian carcinoma. Anticancer Res. 1997 ; 17 (1A). 337-342
37. Hagenbaugh A, Sharma S, Dubinett SM, et al. Altered immune responses in interleukin 10 transgenic mice. J Exp Med. 1997 ; 185 (12). 2101-2110
38. Mahipal A, Terai M, Berd D, et al. Tumor-derived interleukin-10 as a prognostic factor in stage III patients undergoing adjuvant treatment with an autologous melanoma cell vaccine. Cancer Immunol Immunother. 2011 ; 60 (7). 1039-1045
39. Terai M, Tamura Y, Alexeev V, et al. Human interleukin 10 receptor 1/IgG1-Fc fusion proteins: immunoadhesins for human IL-10 with therapeutic potential. Cancer Immunol Immunother. 2009 ; 58 (8). 1307-1317